These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 32267077)

  • 1. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH; Jerkins T
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic agents for the treatment of diabetic kidney disease.
    Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.
    Mazzieri A; Porcellati F; Timio F; Reboldi G
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
    Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
    Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
    Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
    Wang N; Zhang C
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
    Leehey DJ
    Kidney360; 2020 Apr; 1(4):292-299. PubMed ID: 35372914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
    Sugahara M; Pak WLW; Tanaka T; Tang SCW; Nangaku M
    Nephrology (Carlton); 2021 Jun; 26(6):491-500. PubMed ID: 33550672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Stephens JW; Brown KE; Min T
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.